These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 14583457)

  • 41. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
    Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
    Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chromosome instability in fibroblasts derived from Li-Fraumeni syndrome families without TP53 mutations.
    Boyle JM; Spreadborough A; Greaves MJ; Birch JM; Scott D
    Br J Cancer; 2000 Nov; 83(9):1136-8. PubMed ID: 11027425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Li Fraumeni syndrome: a case with multiple primary cancers and presenting a germline p53 mutation].
    Landolsi S; Gharbi O; Zrig M; Gribaa M; Njim L; Zakhama A; Abid A; Frébourg T; Ahmed SB
    Ann Biol Clin (Paris); 2010; 68(3):346-50. PubMed ID: 20478780
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome.
    Rieber J; Remke M; Hartmann C; Korshunov A; Burkhardt B; Sturm D; Mechtersheimer G; Wittmann A; Greil J; Blattmann C; Witt O; Behnisch W; Halatsch ME; Orakcioglu B; von Deimling A; Lichter P; Kulozik A; Pfister S
    Genes Chromosomes Cancer; 2009 Jul; 48(7):558-68. PubMed ID: 19378321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
    Nichols KE; Malkin D; Garber JE; Fraumeni JF; Li FP
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):83-7. PubMed ID: 11219776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative frequency and morphology of cancers in carriers of germline TP53 mutations.
    Birch JM; Alston RD; McNally RJ; Evans DG; Kelsey AM; Harris M; Eden OB; Varley JM
    Oncogene; 2001 Aug; 20(34):4621-8. PubMed ID: 11498785
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
    Lee SB; Kim SH; Bell DW; Wahrer DC; Schiripo TA; Jorczak MM; Sgroi DC; Garber JE; Li FP; Nichols KE; Varley JM; Godwin AK; Shannon KM; Harlow E; Haber DA
    Cancer Res; 2001 Nov; 61(22):8062-7. PubMed ID: 11719428
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TP53, hChk2, and the Li-Fraumeni syndrome.
    Varley J
    Methods Mol Biol; 2003; 222():117-29. PubMed ID: 12710683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
    Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
    Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.
    Sherif ZA; Danielsen M
    Cancer Genet Cytogenet; 2006 Jul; 168(1):50-8. PubMed ID: 16772121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.
    Watanabe T; Vital A; Nobusawa S; Kleihues P; Ohgaki H
    Acta Neuropathol; 2009 Jun; 117(6):653-6. PubMed ID: 19340432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Familial gastric cancer and Li-Fraumeni syndrome.
    Corso G; Pedrazzani C; Marrelli D; Pinto E; Roviello F
    Eur J Cancer Care (Engl); 2010 May; 19(3):377-81. PubMed ID: 19674071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
    Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
    J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome.
    Sugawara W; Arai Y; Kasai F; Fujiwara Y; Haruta M; Hosaka R; Nishida K; Kurosumi M; Kobayashi Y; Akagi K; Kaneko Y
    Genes Chromosomes Cancer; 2011 Jul; 50(7):535-45. PubMed ID: 21484931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
    Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
    Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family.
    Varley JM; Chapman P; McGown G; Thorncroft M; White GR; Greaves MJ; Scott D; Spreadborough A; Tricker KJ; Birch JM; Evans DG; Reddel R; Camplejohn RS; Burn J; Boyle JM
    Oncogene; 1998 Jun; 16(25):3291-8. PubMed ID: 9681828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
    Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
    Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.
    Bougeard G; Renaux-Petel M; Flaman JM; Charbonnier C; Fermey P; Belotti M; Gauthier-Villars M; Stoppa-Lyonnet D; Consolino E; Brugières L; Caron O; Benusiglio PR; Bressac-de Paillerets B; Bonadona V; Bonaïti-Pellié C; Tinat J; Baert-Desurmont S; Frebourg T
    J Clin Oncol; 2015 Jul; 33(21):2345-52. PubMed ID: 26014290
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
    Pötzsch C; Voigtländer T; Lübbert M
    J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences.
    Lammens CR; Aaronson NK; Wagner A; Sijmons RH; Ausems MG; Vriends AH; Ruijs MW; van Os TA; Spruijt L; Gómez García EB; Kluijt I; Nagtegaal T; Verhoef S; Bleiker EM
    J Clin Oncol; 2010 Jun; 28(18):3008-14. PubMed ID: 20479422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.